PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-34.85%
G&A reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-34.85%
Operating expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
-34.85%
Total costs reduction while Drug Manufacturers - Specialty & Generic median is 1.51%. Seth Klarman would investigate advantages.
-32.81%
Interest expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
34.84%
EBITDA growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.16%. Joel Greenblatt would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
34.84%
Income change of 34.84% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
-32.81%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
34.95%
Income change of 34.95% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
34.95%
Income change of 34.95% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
34.48%
EPS change of 34.48% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
34.48%
Diluted EPS change of 34.48% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
0.38%
Share count reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos would check for issues.
0.38%
Diluted share reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.07%. Jim Chanos would check for issues.